Global  

Co-Diagnostics expects to roll out its coronavirus detection test in Europe shortly

Proactive Investors Thursday, 20 February 2020
Co-Diagnostics (NASDAQ:CODX) is on the receiving end of good news as its Logix Smart COVID-19 test, which detects the deadly coronavirus, is close to being rolled out across the European Union after being submitted for formal EU registration. This novel test uses the Utah diagnostics company’s CoPrimer technology to identify the presence of a ribonucleic acid (RNA) associated with a new strain of the sometimes fatal virus, which first struck in the city of Wuhan in China late last year. The virus has since spread from China to infect more than 75,000 people and cause nearly 2,130 deaths, according to data cited by Johns Hopkins Center for Systems Science and Engineering. READ: Co-Diagnostics receives new orders for its vector control tests, equipment from mosquito abatement districts The coronavirus diagnostic test is expected to be available this month in European countries which accept the highly sought-after CE marking as valid regulatory approval. “We are pleased to announce this milestone, which comes after weeks of hard work by our team at Co-Diagnostics to develop a high-performance diagnostic to help prevent the spread of the new strain of coronavirus,” says Dwight Egan, CEO of Co-Diagnostics. “Our patented CoPrimer molecules have unique properties that lead to a significant reduction in false positive test results over other polymerase chain reaction (PCR), but will also allow for enhanced multiplexing, or identifying multiple targets at once, as we iterate the test to include other strains of coronavirus and mutations of COVID-19.” The dossier with the relevant technical file, which was submitted to the Utah company’s European representative, includes a description of the test to support its compliance with the necessary standards to win a CE mark. This information will confirm the test meets the requirements of the European Union’s In-Vitro Diagnostic (IVD) Medical Device directive. Co-Diagnostics will manufacture its coronavirus diagnostic test in a plant set up for the manufacturing of IVD medical devices in Utah. Earlier this month, Co-Diagnostics’ coronavirus diagnostic test caught the eye of analysts at Maxim Group. Enthusiastic about its introduction in China, Maxim analysts tagged the company with a Buy rating and increased its price target to $5 from $2, citing the speed at which the company developed the detection test and its first sales in China. Co-Diagnostics shares moved 6.3% higher to hit $3.20 in afternoon trade on Thursday.
0
shares
ShareTweetSavePostSend
 
Video Credit: Al Jazeera STUDIO - Published
News video: South Korea: Emergency measures after rise in coronavirus cases

South Korea: Emergency measures after rise in coronavirus cases 01:58

Millions of people urged to stay indoors as South Korea becomes the country with the highest number of coronavirus infections outside China.

You Might Like


Related videos from verified sources

Coronavirus Spread Triggers New Travel Restrictions [Video]

Coronavirus Spread Triggers New Travel Restrictions

Travelers entering the United States from Italy, South Korea and Iran will face new restrictions. President Donald Trump and US health officials said Saturday they're part of efforts to curtail the..

Credit: Wochit     Duration: 00:44Published
Coronavirus Update: Washington State Declares Emergency After 1st U.S. Death [Video]

Coronavirus Update: Washington State Declares Emergency After 1st U.S. Death

Washington State has declared a state of emergency after reporting the first person in the U.S. to die of the virus; CBS2's Christina Fan reports.

Credit: CBS 2 New York     Duration: 02:37Published
Coronavirus Update: Local Universities Canceling Study Abroad Programs [Video]

Coronavirus Update: Local Universities Canceling Study Abroad Programs

The University of Connecticut has notified 88 students studying in Italy and one in South Korea to return to the U.S. due to fears of the coronavirus.

Credit: CBS 2 New York     Duration: 00:31Published

Related news from verified sources

Co-Diagnostics wins CE Mark and right to market coronavirus detection test across Europe

Co-Diagnostics Inc (Nasdaq:CODX) has won a critical victory as the diagnostics company can now sell its coronavirus detection test across Europe after clinching...
Proactive Investors

Co-Diagnostics secures $4.2M for coronavirus detection test; shares jump pre-market

Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday a financing plan expected to raise about $4.2 million as it sells its coronavirus detection tests. ...
Proactive Investors

Co-Diagnostics shares surge on report of sales of Coronavirus screening test

Co-Diagnostics Inc (NASDAQ:CODX), a scientific diagnostics company, has announced the first sales of its screening test which successfully identifies the deadly...
Proactive Investors


Tweets about this